With the stock showing a rise of 2.09%, Cipla continues to be a key player in the pharmaceutical sector, demonstrating steady financial performance and active corporate actions.

Cipla share price gain 3% after Q1 earnings beat estimates, with strong margins, India growth, and positive analyst sentiment ...

Cipla Ltd (BOM:500087) reports robust financial performance with significant milestones in India and strategic advancements in the US market.

In a turbulent market, experts recommend five stocks with strong technical indicators for short-term investments. From ...

Cipla, the country’s third-largest drugmaker by market value, was the top gainer on the Nifty 50 on Friday, rising over 3 per ...

Following the earnings announcement, several brokerage firms revised their target price for the stock, with some estimates reaching as high as Rs 1,875 per share, indicating potential for further ...

The market may continue to consolidate with a negative bias in the upcoming sessions. Below are some short-term trading ideas ...

Cipla , India's third-largest drugmaker by sales, reported a better-than-expected quarterly profit on Friday, driven by higher domestic demand for its generic respiratory drugs.

As Cipla turns 90, the pharmaceutical giant is reimagining itself as a brand fit for a wellness-driven, digital-first India.

Cartrade Tech Ltd., Cipla Ltd., Vijay Diagnostic Centre Ltd., Fortis Healthcare Ltd., and Dabur India Ltd. are among the ...

Aurobindo, Cipla and Viatris will develop, manufacture and supply long-acting injectable cabotegravir. Aurobindo, Cipla and ...

Nuvama has maintained a ‘Hold’ rating, raising its target price from Rs 1,620 to Rs 1,651. The brokerage cited strong ...